The estimated Net Worth of Peter D.O. Donhauser is at least $120 Mille dollars as of 14 June 2024. Peter Donhauser owns over 2,835 units of Anavex Life Sciences stock worth over $25,650 and over the last 6 years he sold AVXL stock worth over $0. In addition, he makes $93,871 as Independent Director at Anavex Life Sciences.
Sign up
Peter Donhauser AVXL stock SEC Form 4 insiders trading
Peter has made over 3 trades of the Anavex Life Sciences stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 2,835 units of AVXL stock worth $10,319 on 14 June 2024.
The largest trade he's ever made was buying 2,835 units of Anavex Life Sciences stock on 14 June 2024 worth over $10,319. On average, Peter trades about 500 units every 121 days since 2018. As of 14 June 2024 he still owns at least 5,000 units of Anavex Life Sciences stock.
You can see the complete history of Peter Donhauser stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Donhauser biography
Dr. Peter Donhauser M.D. serves as Independent Director of the Company. He has more than 20 years of expertise in clinical research followed by practicing osteopathic medicine with an integrated medical approach in private practice since 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromusculoskeletal diseases. During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck Sharp & Dohme/Merck, Boehringer Mannheim/Roche, Servier and Sanofi. He received his human medicine degree at the University of Munich and Doctor of Osteopathic Medicine (D.O.) from the DAAO and EROP at the Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania. He has served as a director of the Company since February 8, 2017.
What is the salary of Peter Donhauser?
As the Independent Director of Anavex Life Sciences, the total compensation of Peter Donhauser at Anavex Life Sciences is $93,871. There are 5 executives at Anavex Life Sciences getting paid more, with Christopher Missling having the highest compensation of $3,380,040.
How old is Peter Donhauser?
Peter Donhauser is 54, he's been the Independent Director of Anavex Life Sciences since 2017. There are 2 older and 5 younger executives at Anavex Life Sciences. The oldest executive at Anavex Life Sciences Corporation is Stephan Toutain, 55, who is the Chief Operating Officer.
What's Peter Donhauser's mailing address?
Peter's mailing address filed with the SEC is 630 5TH AVENUE, 20TH FLOOR, , NEW YORK, NY, 10111.
Insiders trading at Anavex Life Sciences
Over the last 18 years, insiders at Anavex Life Sciences have traded over $5,238,591 worth of Anavex Life Sciences stock and bought 135,460 units worth $453,776 . The most active insiders traders include Athanasios Skarpelos, Christopher U Missling e Elliot Favus. On average, Anavex Life Sciences executives and independent directors trade stock every 99 days with the average trade being worth of $335,876. The most recent stock trade was executed by Peter D.O. Donhauser on 14 June 2024, trading 2,835 units of AVXL stock currently worth $10,319.
What does Anavex Life Sciences do?
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
What does Anavex Life Sciences's logo look like?
Complete history of Peter Donhauser stock trades at Anavex Life Sciences
Anavex Life Sciences executives and stock owners
Anavex Life Sciences executives and other stock owners filed with the SEC include:
-
Christopher Missling,
President, Chief Executive Officer, Secretary, Director -
Dr. Christopher U. Missling,
Chairman, Pres, CEO & Sec. -
Sandra Boenisch,
Principal Financial Officer, Treasurer -
Sandra Boenisch CPA, CPA, CGA,
Principal Financial Officer & Treasurer -
Claus van der Velden,
Independent Director -
Steffen Thomas,
Independent Director -
Athanasios Skarpelos,
Independent Director -
Elliot Favus,
Independent Director -
Peter Donhauser,
Independent Director -
Dr. Adebayo Laniyonu Ph.D.,
Sr. VP of Nonclinical Devel. -
Clint Tomlinson,
VP of Corp. -
Dr. Walter E. Kaufmann M.D.,
Chief Medical Officer -
Dr. Emmanuel O. Fadiran RPh, Ph.D.,
Sr. VP of Regulatory Affairs -
Stephan Toutain,
Chief Operating Officer -
Bernd Metzner,
Director -
Jiong Ma,
Director -
Cameron Durrant,
Director -
Harvey Lalach,
President, CFO -
Alison E. Ayers,
Director -
David L. Tousley,
Director -
George F Tidmarsh,
Executive Director -
Panos Kontzalis,
CEO -
George Kalkanis,
VP Strategic Planning -
Angela Vernadaki,
VP Business Development